- A phlebotomy technician is implementing a new lot of control material for a point-of-care cardiac marker analyzer. The previous lot had a target range of 2.5-4.5 ng/mL, but the new lot package insert shows 3.2-5.8 ng/mL. Before using the new controls, what validation step is most critical?
Answer: Run both old and new control lots simultaneously for at least 5 days to establish continuity and verify the manufacturer's stated ranges
When implementing new control lots with different target ranges, running both lots simultaneously helps verify the new ranges are appropriate for your specific instrument and establishes continuity between lots. This validates that the range change reflects lot differences, not instrument problems. Option B ignores the need for institutional validation of new materials. Option C inappropriately adjusts patient results based on control differences. Option D unnecessarily involves the manufacturer when standard validation procedures are sufficient.
- A new lot of CLIA-waived POC strips is opened; previous lot passed QC. What is needed?
Answer: Run control on the new lot
Each new lot of test strips must be validated before patient use, even if the previous lot passed QC. Running a control on the new lot verifies that these strips perform correctly. Using the previous lot's QC result is wrong because it does not apply to the new lot's performance.
- A CLIA-waived POC control is past open-date stability but the QC result is in range. What is the correct action?
Answer: Discard; rerun with fresh vial
Open-date stability defines the maximum usable life; once past it the control is no longer valid even if the result looks acceptable. The in-range reading could be false reassurance from degraded material, so you must discard the old vial and repeat QC with fresh control. Accepting the result is the tempting error because the number is in range, but stability expiration overrides the numerical result.
- During monthly quality control review, a phlebotomy technician notices that one glucose meter consistently produces control results in the upper portion of the acceptable range (110-118 mg/dL from a 90-120 mg/dL range), while two identical meters produce results in the lower portion (92-98 mg/dL). All results are technically within range. What quality assurance concern does this pattern indicate?
Answer: Systematic bias between meters that could affect patient care decisions when the same patient is tested on different instruments
Even when individual meters pass QC, systematic differences between instruments can create clinically significant bias affecting patient care decisions. This situation requires investigation and possible corrective action to ensure consistency across the testing network. Option A ignores the clinical implications of inter-instrument bias. Option B assumes the high-reading meter is wrong without proper investigation. Option D incorrectly classifies this as normal variation when it represents a quality assurance concern.
- A CLIA-waived POC analyzer's internal control passed, but liquid QC is due today. What should occur?
Answer: Run liquid QC as scheduled
Liquid QC is required at its scheduled time regardless of a passing internal control. The internal control only checks the test system, not the full testing process. Skipping because internal control passed is the tempting error; it does not replace liquid QC. Run liquid QC as scheduled.
- While performing quality control on a point-of-care coagulation analyzer, a phlebotomy technician observes that the normal control consistently passes (11.2-11.8 seconds, range 10.5-12.0), but the abnormal control has failed three consecutive times (25.1, 24.8, 25.3 seconds, range 26.0-30.0). What systematic issue should be investigated first?
Answer: Temperature stability of the abnormal control solution, since coagulation factors are more sensitive to storage conditions at prolonged clotting times
Abnormal coagulation controls contain factors that are more temperature-sensitive than normal controls. The consistently low results (faster clotting times) suggest temperature-related degradation of clotting factors in the abnormal control. Option B incorrectly assumes volume differences between control types. Option C doesn't explain why only the abnormal control is affected. Option D misunderstands that optical issues would likely affect both control levels similarly.
- CLIA-waived POC manufacturer requires two control levels daily; only level 1 passed before testing. Are results valid?
Answer: Invalid until level 2 passes
Manufacturer QC requirements are a package deal: both control levels must be in range before patient testing. Testing with only level 1 passed skips part of the required verification, so results are not valid until level 2 also passes. The tempting mistake is thinking one in-range control is enough, but level 2 is needed to check the other assay range.
- A phlebotomy technician is performing quality control on a glucose meter used for point-of-care testing. The control solution package insert indicates the acceptable range is 80-120 mg/dL. Over three consecutive days, the control results are: Day 1: 118 mg/dL, Day 2: 125 mg/dL, Day 3: 119 mg/dL. What is the most appropriate action?
Answer: Repeat the out-of-range control, investigate potential causes, and do not perform patient testing until corrective action is taken
When any quality control result falls outside the acceptable range, CLIA regulations require immediate corrective action. Patient testing must be suspended until the problem is identified and resolved. Option A is incorrect because any out-of-range control invalidates the testing system. Option C is incorrect because individual controls must each be within range, not averaged. Option D is incorrect because control values are not patient results and do not get reported as critical values.
- During point-of-care cholesterol testing, a phlebotomy technician discovers that the high-level cholesterol control expired yesterday but the low-level control is still valid for 30 days. The department protocol requires both levels of controls to be run before patient testing. How should this situation be handled?
Answer: Suspend patient testing until new high-level controls arrive and both levels can be run within their expiration dates
Expired controls cannot be used as they may not perform as expected, potentially masking instrument problems. When departmental protocols require both control levels, both must be valid before patient testing can proceed. Option A violates the department's two-level protocol. Option B uses expired materials which compromises quality assurance. Option D creates an unvalidated control that doesn't meet manufacturer specifications or regulatory requirements.
- A phlebotomy technician notices that pregnancy test controls have been consistently at the lower end of the acceptable range for five consecutive days, though still within the manufacturer's specified limits. The positive control target is 50-150 mIU/mL, and recent results are 52, 55, 51, 54, and 53 mIU/mL. What quality assurance principle does this pattern represent?
Answer: A systematic shift indicating potential reagent degradation or instrument drift requiring investigation and possible recalibration
A systematic shift or trend, even within acceptable limits, indicates a developing problem that should be investigated before it becomes an out-of-control situation. This pattern suggests reagent degradation or instrument drift. Option A ignores the trending pattern which is a quality assurance red flag. Option C misinterprets the situation - while precision appears good, the consistent low values indicate bias. Option D incorrectly suggests this is normal trending when it actually represents a concerning pattern.
- A phlebotomy technician discovers that the laboratory's point-of-care testing coordinator has been absent for a week, and no quality controls have been performed on the department's three glucose meters during this time. Patient testing has continued daily. What regulatory and quality assurance issues must be addressed?
Answer: Suspend all glucose testing, run controls on each meter, investigate any failures, and document the control lapse according to institutional policy
When you encounter point-of-care testing (POCT) quality control failures, remember that patient safety and regulatory compliance require immediate, comprehensive action. Quality control testing ensures the accuracy and reliability of patient results, and gaps in QC create serious liability issues.
Option D is correct because it follows proper POCT protocol: immediately suspend testing to prevent potentially inaccurate results, run controls to assess current meter performance, investigate any control failures to determine if the meters were functioning properly during the lapse, and document everything according to institutional policy. This approach prioritizes patient safety while gathering data needed for proper remediation.
Option A is problematic because you cannot retroactively validate patient results simply through documentation review when controls weren't performed. Control testing verifies instrument accuracy at the time of testing, and this verification cannot be applied backward in time.
Option B overreacts by involving CLIA authorities immediately and requiring external validation. While CLIA compliance is important, the first step is internal assessment and remediation following your facility's established procedures.
Option C assumes all previous results are invalid and requires patient notification regardless of current control performance. This creates unnecessary patient anxiety and healthcare costs without proper assessment of actual meter performance during the control gap.
Remember: POCT quality control lapses require immediate testing suspension, current control assessment, failure investigation, and thorough documentation. Never assume instruments were accurate without controls, but also don't assume they were inaccurate until you have evidence.
- A CLIA-waived POC control is out of range. What must happen before patient testing resumes?
Answer: Resolve the issue; pass QC
An out-of-range control means the test system may be unreliable, so patient results are not trustworthy until the problem is found and a new control run passes. Repeating the patient sample doesn't address the failed control, and switching lots or reporting only critical values still skips required QC. You must resolve the issue and pass QC before testing resumes.
- While performing quality control on a point-of-care INR analyzer, a phlebotomy technician obtains a control result of 2.8 when the target range is 2.0-3.0. However, the instrument displays a "QC Warning" message indicating the result is at the edge of acceptable performance. What is the most appropriate interpretation of this situation?
Answer: The warning indicates potential instrument problems despite the acceptable numerical result, requiring investigation before patient testing continues
When you encounter quality control questions on point-of-care testing devices, focus on understanding that numerical results and instrument alerts serve different but equally important functions in ensuring patient safety.
Option D is correct because modern analyzers use sophisticated algorithms that evaluate multiple parameters beyond just the final numerical result. The "QC Warning" message indicates the instrument has detected subtle variations in measurement patterns, reagent performance, or internal system checks that could affect reliability. Even though 2.8 falls within the 2.0-3.0 range, the warning suggests the measurement process isn't operating optimally. Professional standards require investigating any QC alerts before proceeding with patient testing to prevent potentially inaccurate results.
Option A is wrong because it ignores critical safety protocols—you should never dismiss instrument warnings simply because numbers appear acceptable. Option B incorrectly treats a warning as a critical failure; warnings indicate caution needed, not emergency situations requiring immediate shutdown. Option C focuses too narrowly on repeating the control and automatic recalibration, missing the broader need for systematic troubleshooting to identify the root cause of the warning.
Remember this key principle for the CPT exam: Quality control isn't just about numbers falling within ranges—it's about ensuring the entire measurement system functions properly. When instruments generate warnings or flags, always investigate before proceeding with patient testing, regardless of whether numerical results appear acceptable. This demonstrates proper quality assurance practices that protect patient safety.
- When performing quality control for a CLIA-waived hemoglobin analyzer, a phlebotomy technician obtains a control result of 10.2 g/dL when the expected range is 11.8-13.2 g/dL. After repeating the control with the same result, what combination of corrective actions should be performed before resuming patient testing?
Answer: Clean the analyzer optics, verify control solution expiration date, and run a new control from a different lot number
Systematic troubleshooting requires checking multiple potential causes: optical interference (cleaning), control integrity (expiration), and control variation (different lot). This comprehensive approach addresses the most common causes of QC failures. Option B suggests immediate calibration without troubleshooting simpler causes first. Option C doesn't address potential optical or mixing issues. Option D repeats the same control that already failed twice, which wastes time and resources.
- A phlebotomy technician is training a new employee on urinalysis quality control procedures. The trainer explains that specific gravity controls must be run each day before patient testing. If the specific gravity control reads 1.018 when the acceptable range is 1.015-1.020, but the glucose control fails, what should the trainee understand about proceeding with urinalysis testing?
Answer: All urinalysis testing must be suspended regardless of which individual control passed, until all controls are within acceptable ranges
Quality control failures for any parameter on a multi-test system require suspension of the entire testing process until all controls pass. This ensures complete system integrity. Option A incorrectly suggests partial testing is acceptable when QC fails. Option C wrongly assumes one passing control validates unrelated test parameters. Option D misunderstands that QC applies to the entire analytical system, not just automated portions.
